Neurotech International Validates Benefits of Cannabinoid Therapy in Pediatric Patients; Shares Rise 4%

MT Newswires Live09-09

Neurotech International (ASX:NTI) validated the benefits of its cannabinoid therapy NTI164 following a genome analysis of a phase 1 trial investigating its use in pediatric patients, according to a Monday filing with the Australian bourse.

The study showed that the therapy was able to modify immune cell function and gene dysregulation, improving patient outcomes, the filing said.

The trial was conducted in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, or PANDAS, and pediatric acute-onset neuropsychiatric syndrome, or PANS, the filing added.

Shares of Neurotech International rose past 4% in recent Monday trade.

Price (AUD): $0.07, Change: $+0.0030, Percent Change: +4.41%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466180940?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-09 13:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466180940","market":"fut","top_or_hot":-1,"title":"Neurotech International Validates Benefits of Cannabinoid Therapy in Pediatric Patients; Shares Rise 4%","media":"MT Newswires Live","content":"<html><body><p> Neurotech International (ASX:NTI) validated the benefits of its cannabinoid therapy NTI164 following a genome analysis of a phase 1 trial investigating its use in pediatric patients, according to a Monday filing with the Australian bourse.</p><p>The study showed that the therapy was able to modify immune cell function and gene dysregulation, improving patient outcomes, the filing said.</p><p>The trial was conducted in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, or PANDAS, and pediatric acute-onset neuropsychiatric syndrome, or PANS, the filing added.</p><p>Shares of Neurotech International rose past 4% in recent Monday trade.</p><p>Price (AUD): $0.07, Change: $+0.0030, Percent Change: +4.41%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurotech International Validates Benefits of Cannabinoid Therapy in Pediatric Patients; Shares Rise 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurotech International Validates Benefits of Cannabinoid Therapy in Pediatric Patients; Shares Rise 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-09 13:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neurotech International (ASX:NTI) validated the benefits of its cannabinoid therapy NTI164 following a genome analysis of a phase 1 trial investigating its use in pediatric patients, according to a ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4125","symbol_name":"广播","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466180940","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466180940","pubTimestamp":1725859399,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurotech International  validated the benefits of its cannabinoid therapy NTI164 following a genome analysis of a phase 1 trial investigating its use in pediatric patients, according to a Monday filing with the Australian bourse.The study showed that the therapy was able to modify immune cell function and gene dysregulation, improving patient outcomes, the filing said.The trial was conducted in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, or PANDAS, and pediatric acute-onset neuropsychiatric syndrome, or PANS, the filing added.Shares of Neurotech International rose past 4% in recent Monday trade.Price : $0.07, Change: $+0.0030, Percent Change: +4.41%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4125":"广播","AUD":"Audacy Inc.","NTI.AU":"NEUROTECH INTERNATIONAL LTD","BK7007":"医疗保健设备"},"translate_title":"Neurotech International验证了大麻素治疗对儿科患者的益处；股价上涨4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"NTI.AU":0.9},"content_text":"Neurotech International (ASX:NTI) validated the benefits of its cannabinoid therapy NTI164 following a genome analysis of a phase 1 trial investigating its use in pediatric patients, according to a Monday filing with the Australian bourse.The study showed that the therapy was able to modify immune cell function and gene dysregulation, improving patient outcomes, the filing said.The trial was conducted in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, or PANDAS, and pediatric acute-onset neuropsychiatric syndrome, or PANS, the filing added.Shares of Neurotech International rose past 4% in recent Monday trade.Price (AUD): $0.07, Change: $+0.0030, Percent Change: +4.41%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466180940"}